{
    "info": {
        "nct_id": "NCT06313502",
        "official_title": "High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders",
        "inclusion_criteria": "1. Subject has provided informed consent.\n2. Participants who are 18 years of age or older\n3. Subjects who have been previously treated with 3 or more lines of therapy (i.e., proteasome inhibitors, immunomodulatory agents such as lenalidomide, and monoclonal antibodies such as daratumumab) and have progressed within past 6 months.\n4. Subjects who have at least 1x106/kg CD34 stem cells in storage\n5. Subjects must have measurable disease (as determined by the UAMS clinical lab), including at least one of the criteria below. Tests performed as SOC within 30 days of the first dose may be utilized:\n\n   * M-protein quantities ≥ 0.5 gm/dl by SPEP\n   * ≥ 200 mg/24-hour urine collection by UPEP\n   * serum-free light chain levels > 100 mg/L (milligrams/liter involved light chain) and an abnormal kappa/lambda (κ/λ) ratio in subjects without detectable serum or urine m-protein\n   * a serum IgA level ≥ 500 mg/dL for subjects with immunoglobulin class A (IgA) myeloma whose disease can only be reliably measured by quantitative immunoglobulin measurement\n   * Non-secretory subjects are eligible provided the subject has > 20% BM plasmacytosis, OR multiple plasmacytomas or lesions (≥3) on MRI at the time of diagnosis or study enrollment, OR the presence of lesions (≥ 3) on PET/Computerized Tomography (CT) scan.\n6. Adequate organ function reflects the following:\n\n   * Absolute neutrophil count (ANC) ≥ 0.5 x 109/L without growth factor support for 7 days (14 days if pegfilgastrim).\n   * Platelets ≥ 25 x 109/L without transfusion for 7 days. However, subject can be enrolled if the ANC and platelets are low due to disease\n   * Potassium within normal limits or correctable with supplements\n   * Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x upper limit of normal (ULN)\n   * Serum bilirubin ≤ 1.5 x ULN\n   * Estimated serum creatinine clearance of ≥ 45 mL/min using the Cockcroft-Gault equation or directly calculated from the 24-hour urine collection method\n   * International normalized ratio (INR) < 1.5 x ULN and partial thromboplastin time < 1.5 x ULN\n   * Ejection fraction by ECHO or MUGA of ≥ 40% performed\n   * Subjects must have adequate pulmonary function studies (PFTs) > 50% of predicted on mechanical aspects (forced expiratory volume, forced vital capacity) and > 50% of predicted (adjusted for hemoglobin) on diffusion capacity. If the participant is unable to complete PFTs due to disease-related pain or other circumstances that make it difficult to reliably perform PFTs, documentation of pulmonary function adequate for transplant will occur via a CT scan without evidence of major pulmonary disease and arterial blood gas results.\n7. Subjects must have a performance status of 0-2 based on ECOG performance criteria. Subjects with poor performance status (3-4) based solely on bone pain will be eligible if there is documentation to verify this.\n8. Negative serum or urine pregnancy test (sensitivity of at least 25 mIU/mL) at screening.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
        "exclusion_criteria": "1. Prior allogeneic transplant.\n2. Known hypersensitivity or allergy to ascorbic acid or melphalan, or any Grade 3 or higher AE as a result of test dose given during screening (15 gm).\n3. Subjects must not have a concurrent malignancy unless it can be adequately treated by non-chemotherapeutic intervention. Participants may have a history of prior malignancy without any chemotherapy within 365 days of study entry AND life expectancy exceeding 5 years at the time of study entry.\n4. Subjects must not have life-threatening comorbidities as assessed by the investigator.\n5. History or evidence of MM associated with immunodeficiency states (e.g., hereditary immune deficiency, human immunodeficiency virus (HIV), organ transplant, or leukemia).\n6. Known HIV disease (requires negative test for clinically suspected HIV infection).\n7. Evidence of CNS myeloma.\n8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, recent (within 6 months) myocardial infarction, uncontrolled or symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension on appropriate therapy or psychiatric illness/social situations that would limit compliance with study requirements.\n9. Concurrent use of coumadin (warfarin).\n10. Glucose-6-phosphate dehydrogenase deficiency as defined by blood test at screening visit.\n11. Pre-existing renal insufficiency or renal failure, a known history of renal stones, or who are undergoing dialysis.\n12. Diabetic subjects who are insulin dependent.\n13. Any other condition that, in the opinion of the investigator, might interfere with the safe conduct of the study.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "7. Subjects must have a performance status of 0-2 based on ECOG performance criteria. Subjects with poor performance status (3-4) based solely on bone pain will be eligible if there is documentation to verify this.",
            "criterions": [
                {
                    "exact_snippets": "performance status of 0-2 based on ECOG performance criteria",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with poor performance status (3-4) based solely on bone pain will be eligible if there is documentation to verify this",
                    "criterion": "ECOG performance status due to bone pain",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": ""
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "bone pain"
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Adequate organ function reflects the following:",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum bilirubin ≤ 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Serum bilirubin ≤ 1.5 x ULN",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects must have adequate pulmonary function studies (PFTs) > 50% of predicted on mechanical aspects (forced expiratory volume, forced vital capacity) and > 50% of predicted (adjusted for hemoglobin) on diffusion capacity. If the participant is unable to complete PFTs due to disease-related pain or other circumstances that make it difficult to reliably perform PFTs, documentation of pulmonary function adequate for transplant will occur via a CT scan without evidence of major pulmonary disease and arterial blood gas results.",
            "criterions": [
                {
                    "exact_snippets": "adequate pulmonary function studies (PFTs) > 50% of predicted on mechanical aspects (forced expiratory volume, forced vital capacity)",
                    "criterion": "pulmonary function (mechanical aspects: FEV, FVC)",
                    "requirements": [
                        {
                            "requirement_type": "percentage of predicted value",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "forced expiratory volume",
                                "forced vital capacity"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "> 50% of predicted (adjusted for hemoglobin) on diffusion capacity",
                    "criterion": "pulmonary diffusion capacity",
                    "requirements": [
                        {
                            "requirement_type": "percentage of predicted value (adjusted for hemoglobin)",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "test type",
                            "expected_value": "diffusion capacity"
                        }
                    ]
                },
                {
                    "exact_snippets": "If the participant is unable to complete PFTs ... documentation of pulmonary function adequate for transplant will occur via a CT scan without evidence of major pulmonary disease",
                    "criterion": "major pulmonary disease on CT scan",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "If the participant is unable to complete PFTs ... documentation of pulmonary function adequate for transplant will occur via ... arterial blood gas results",
                    "criterion": "arterial blood gas results adequate for transplant",
                    "requirements": [
                        {
                            "requirement_type": "adequacy for transplant",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 100 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 100 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 100,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ejection fraction by ECHO or MUGA of ≥ 40% performed",
            "criterions": [
                {
                    "exact_snippets": "Ejection fraction by ECHO or MUGA of ≥ 40% performed",
                    "criterion": "ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "ECHO",
                                "MUGA"
                            ]
                        },
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "performed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Subjects who have been previously treated with 3 or more lines of therapy (i.e., proteasome inhibitors, immunomodulatory agents such as lenalidomide, and monoclonal antibodies such as daratumumab) and have progressed within past 6 months.",
            "criterions": [
                {
                    "exact_snippets": "Subjects who have been previously treated with 3 or more lines of therapy",
                    "criterion": "number of prior lines of therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "previously treated with ... proteasome inhibitors, immunomodulatory agents such as lenalidomide, and monoclonal antibodies such as daratumumab",
                    "criterion": "prior therapy classes received",
                    "requirements": [
                        {
                            "requirement_type": "classes received",
                            "expected_value": [
                                "proteasome inhibitors",
                                "immunomodulatory agents",
                                "monoclonal antibodies"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have progressed within past 6 months",
                    "criterion": "disease progression timing",
                    "requirements": [
                        {
                            "requirement_type": "progression interval",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Potassium within normal limits or correctable with supplements",
            "criterions": [
                {
                    "exact_snippets": "Potassium within normal limits",
                    "criterion": "potassium level",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": "within normal limits"
                        }
                    ]
                },
                {
                    "exact_snippets": "correctable with supplements",
                    "criterion": "potassium level",
                    "requirements": [
                        {
                            "requirement_type": "correctability with supplements",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Estimated serum creatinine clearance of ≥ 45 mL/min using the Cockcroft-Gault equation or directly calculated from the 24-hour urine collection method",
            "criterions": [
                {
                    "exact_snippets": "Estimated serum creatinine clearance of ≥ 45 mL/min using the Cockcroft-Gault equation or directly calculated from the 24-hour urine collection method",
                    "criterion": "serum creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "estimation_method",
                            "expected_value": [
                                "Cockcroft-Gault equation",
                                "24-hour urine collection method"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* M-protein quantities ≥ 0.5 gm/dl by SPEP",
            "criterions": [
                {
                    "exact_snippets": "M-protein quantities ≥ 0.5 gm/dl by SPEP",
                    "criterion": "M-protein quantity",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "gm/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ≥ 200 mg/24-hour urine collection by UPEP",
            "criterions": [
                {
                    "exact_snippets": "≥ 200 mg/24-hour urine collection by UPEP",
                    "criterion": "urine protein excretion (UPEP)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "mg/24-hour"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalized ratio (INR) < 1.5 x ULN and partial thromboplastin time < 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) < 1.5 x ULN",
                    "criterion": "International normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "partial thromboplastin time < 1.5 x ULN",
                    "criterion": "partial thromboplastin time",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase ... ≤ 2.5 x upper limit of normal (ULN)",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase ≤ 2.5 x upper limit of normal (ULN)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Participants who are 18 years of age or older",
            "criterions": [
                {
                    "exact_snippets": "Participants who are 18 years of age or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-secretory subjects are eligible provided the subject has > 20% BM plasmacytosis, OR multiple plasmacytomas or lesions (≥3) on MRI at the time of diagnosis or study enrollment, OR the presence of lesions (≥ 3) on PET/Computerized Tomography (CT) scan.",
            "criterions": [
                {
                    "exact_snippets": "Non-secretory subjects are eligible",
                    "criterion": "secretory status",
                    "requirements": [
                        {
                            "requirement_type": "secretory",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "> 20% BM plasmacytosis",
                    "criterion": "bone marrow plasmacytosis",
                    "requirements": [
                        {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": ">",
                                "value": 20,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "multiple plasmacytomas or lesions (≥3) on MRI at the time of diagnosis or study enrollment",
                    "criterion": "plasmacytomas or lesions on MRI",
                    "requirements": [
                        {
                            "requirement_type": "number of lesions or plasmacytomas",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "imaging modality",
                            "expected_value": "MRI"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "diagnosis",
                                "study enrollment"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of lesions (≥ 3) on PET/Computerized Tomography (CT) scan",
                    "criterion": "lesions on PET/CT scan",
                    "requirements": [
                        {
                            "requirement_type": "number of lesions",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "imaging modality",
                            "expected_value": [
                                "PET",
                                "CT"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* a serum IgA level ≥ 500 mg/dL for subjects with immunoglobulin class A (IgA) myeloma whose disease can only be reliably measured by quantitative immunoglobulin measurement",
            "criterions": [
                {
                    "exact_snippets": "a serum IgA level ≥ 500 mg/dL",
                    "criterion": "serum IgA level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 500,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with immunoglobulin class A (IgA) myeloma",
                    "criterion": "immunoglobulin class A (IgA) myeloma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "whose disease can only be reliably measured by quantitative immunoglobulin measurement",
                    "criterion": "disease measurability by quantitative immunoglobulin measurement",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": "can only be reliably measured by quantitative immunoglobulin measurement"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* serum-free light chain levels > 100 mg/L (milligrams/liter involved light chain) and an abnormal kappa/lambda (κ/λ) ratio in subjects without detectable serum or urine m-protein",
            "criterions": [
                {
                    "exact_snippets": "serum-free light chain levels > 100 mg/L (milligrams/liter involved light chain)",
                    "criterion": "serum-free light chain levels",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "mg/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "abnormal kappa/lambda (κ/λ) ratio",
                    "criterion": "kappa/lambda ratio",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "abnormal"
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects without detectable serum or urine m-protein",
                    "criterion": "serum or urine m-protein",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Negative serum or urine pregnancy test (sensitivity of at least 25 mIU/mL) at screening.",
            "criterions": [
                {
                    "exact_snippets": "Negative serum or urine pregnancy test",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "serum or urine pregnancy test (sensitivity of at least 25 mIU/mL)",
                    "criterion": "pregnancy test sensitivity",
                    "requirements": [
                        {
                            "requirement_type": "sensitivity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "mIU/mL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at screening",
                    "criterion": "timing of pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Subjects must have measurable disease (as determined by the UAMS clinical lab), including at least one of the criteria below. Tests performed as SOC within 30 days of the first dose may be utilized:",
            "criterions": [
                {
                    "exact_snippets": "Subjects must have measurable disease (as determined by the UAMS clinical lab)",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "UAMS clinical lab"
                        }
                    ]
                },
                {
                    "exact_snippets": "Tests performed as SOC within 30 days of the first dose may be utilized",
                    "criterion": "disease assessment tests",
                    "requirements": [
                        {
                            "requirement_type": "test_type",
                            "expected_value": "standard of care (SOC)"
                        },
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Subject has provided informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Subject has provided informed consent.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provided",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "6. Known HIV disease (requires negative test for clinically suspected HIV infection).",
            "criterions": [
                {
                    "exact_snippets": "Known HIV disease (requires negative test for clinically suspected HIV infection)",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Concurrent use of coumadin (warfarin).",
            "criterions": [
                {
                    "exact_snippets": "Concurrent use of coumadin (warfarin)",
                    "criterion": "coumadin (warfarin) use",
                    "requirements": [
                        {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Subjects must not have a concurrent malignancy unless it can be adequately treated by non-chemotherapeutic intervention. Participants may have a history of prior malignancy without any chemotherapy within 365 days of study entry AND life expectancy exceeding 5 years at the time of study entry.",
            "criterions": [
                {
                    "exact_snippets": "Subjects must not have a concurrent malignancy unless it can be adequately treated by non-chemotherapeutic intervention.",
                    "criterion": "concurrent malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "treatment type if present",
                            "expected_value": "adequately treated by non-chemotherapeutic intervention"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants may have a history of prior malignancy without any chemotherapy within 365 days of study entry",
                    "criterion": "history of prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "chemotherapy within 365 days of study entry",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "life expectancy exceeding 5 years at the time of study entry",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Prior allogeneic transplant.",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic transplant.",
                    "criterion": "allogeneic transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Diabetic subjects who are insulin dependent.",
            "criterions": [
                {
                    "exact_snippets": "Diabetic subjects",
                    "criterion": "diabetes",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "insulin dependent",
                    "criterion": "insulin dependence",
                    "requirements": [
                        {
                            "requirement_type": "dependence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Glucose-6-phosphate dehydrogenase deficiency as defined by blood test at screening visit.",
            "criterions": [
                {
                    "exact_snippets": "Glucose-6-phosphate dehydrogenase deficiency as defined by blood test at screening visit",
                    "criterion": "Glucose-6-phosphate dehydrogenase deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method of assessment",
                            "expected_value": "blood test at screening visit"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Pre-existing renal insufficiency or renal failure, a known history of renal stones, or who are undergoing dialysis.",
            "criterions": [
                {
                    "exact_snippets": "Pre-existing renal insufficiency",
                    "criterion": "renal insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "renal failure",
                    "criterion": "renal failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "a known history of renal stones",
                    "criterion": "renal stones",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "undergoing dialysis",
                    "criterion": "dialysis",
                    "requirements": [
                        {
                            "requirement_type": "current treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. History or evidence of MM associated with immunodeficiency states (e.g., hereditary immune deficiency, human immunodeficiency virus (HIV), organ transplant, or leukemia).",
            "criterions": [
                {
                    "exact_snippets": "History or evidence of MM associated with immunodeficiency states",
                    "criterion": "multiple myeloma (MM) associated with immunodeficiency states",
                    "requirements": [
                        {
                            "requirement_type": "history or evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hereditary immune deficiency",
                    "criterion": "hereditary immune deficiency",
                    "requirements": [
                        {
                            "requirement_type": "history or evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "human immunodeficiency virus (HIV)",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history or evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "organ transplant",
                    "criterion": "organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history or evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "leukemia",
                    "criterion": "leukemia",
                    "requirements": [
                        {
                            "requirement_type": "history or evidence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Evidence of CNS myeloma.",
            "criterions": [
                {
                    "exact_snippets": "Evidence of CNS myeloma",
                    "criterion": "CNS myeloma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Any other condition that, in the opinion of the investigator, might interfere with the safe conduct of the study.",
            "criterions": [
                {
                    "exact_snippets": "Any other condition that, in the opinion of the investigator, might interfere with the safe conduct of the study.",
                    "criterion": "other condition interfering with safe conduct of the study",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, recent (within 6 months) myocardial infarction, uncontrolled or symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension on appropriate therapy or psychiatric illness/social situations that would limit compliance with study requirements.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "ongoing or active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "ongoing",
                                "active"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "recent (within 6 months) myocardial infarction",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled or symptomatic congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled hypertension on appropriate therapy",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "therapy",
                            "expected_value": "on appropriate therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness/social situations that would limit compliance with study requirements",
                    "criterion": "psychiatric illness or social situations limiting compliance",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Subjects must not have life-threatening comorbidities as assessed by the investigator.",
            "criterions": [
                {
                    "exact_snippets": "must not have life-threatening comorbidities",
                    "criterion": "life-threatening comorbidities",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "as assessed by the investigator",
                    "criterion": "investigator assessment of comorbidities",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "by investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Known hypersensitivity or allergy to ascorbic acid or melphalan, or any Grade 3 or higher AE as a result of test dose given during screening (15 gm).",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity or allergy to ascorbic acid",
                    "criterion": "hypersensitivity or allergy to ascorbic acid",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity or allergy to ... melphalan",
                    "criterion": "hypersensitivity or allergy to melphalan",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any Grade 3 or higher AE as a result of test dose given during screening (15 gm)",
                    "criterion": "adverse event (AE) after test dose during screening",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "CTCAE grade"
                            }
                        },
                        {
                            "requirement_type": "causality",
                            "expected_value": "as a result of test dose given during screening (15 gm)"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Platelets ≥ 25 x 109/L without transfusion for 7 days. However, subject can be enrolled if the ANC and platelets are low due to disease",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥ 25 x 10^9/L without transfusion for 7 days",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "x 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "transfusion-free duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "subject can be enrolled if the ANC and platelets are low due to disease",
                    "criterion": "low ANC and platelets due to disease",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": "disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) ≥ 0.5 x 109/L without growth factor support for 7 days (14 days if pegfilgastrim).",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥ 0.5 x 10^9/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without growth factor support for 7 days (14 days if pegfilgastrim)",
                    "criterion": "growth factor support",
                    "requirements": [
                        {
                            "requirement_type": "absence duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "absence duration (if pegfilgastrim)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Subjects who have at least 1x106/kg CD34 stem cells in storage",
            "criterions": [
                {
                    "exact_snippets": "at least 1x10^6/kg CD34 stem cells in storage",
                    "criterion": "CD34 stem cells in storage",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000000,
                                "unit": "per kg"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}